Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Domenica LorussoFelix HilpertAntonio González MartinJoern RauPetronella OttevangerElfriede GreimelHans-Joachim LückFrédéric SelleNicoletta ColomboJudith R KroepMansoor R MirzaRegina BergerBeatriz PardoEva-Maria GrischkeDominique Berton-RigaudJeronimo Martinez-GarciaIgnace VergoteAndrés RedondoAndrés CardonaLydie Bastière-TruchotAndreas du BoisChristian Kurzedernull nullPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2019)
Consistent with the primary results, adding pertuzumab to chemotherapy for low tumor HER3 mRNA-expressing platinum-resistant ovarian cancer did not improve overall survival, but showed trends in some cohorts. Except for increased diarrhea symptoms, pertuzumab had no impact on patient-reported outcomes. ClinicalTrials.gov: ClinicalTrials.gov: NCT01684878.
Keyphrases